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ABSTRACT
Thrombocytopenia is one of the two most common hematological problems in pregnant women. It is defined as the 
platelet (PLT) count below 150 × 103/μL. Gestational incidental thrombocytopenia (GIT) represents about 75% of throm-
bocytopenia cases in pregnancy and it is believed that GIT is secondary to accelerated platelet destruction and increased 
plasma volume associated with pregnancy. The pregnancy complications such as preeclampsia and its most severe form 
— HELLP syndrome account for 20% cases of thrombocytopenia in pregnancy and primary immune thrombocytopenic 
purpura (ITP) — for 3–4 percent. During ITP, maternal antiplatelet antibodies can pass through the placenta and bind to 
fetal thrombocytes leading to the development of fetal thrombocytopenia which occurs in about 50% cases. Even if the 
maternal platelet count stabilizes, the estimated fetal and neonatal risk of thrombocytopenia in ITP is approximately 30%. 
Other types of thrombocytopenia in pregnant women constitute 1–2% of cases (disseminated intravascular coagulation, 
autoimmunological diseases, congenital, infection and drug-related, concomitant with blood neoplastic diseases). Although 
thrombocytopenia in pregnant women usually has a mild course, in case of a significant decrease in PLT count may lead 
to dangerous bleeding, especially when the platelet count falls below 20 × 103/μL.
Since it is important to identify the cause of thrombocytopenia and to determine the risk for both the mother and the 
child, this paper presents the influence of maternal thrombocytopenia on the pregnancy course as well as its etiology and 
diagnostics. The treatment principles are discussed. 
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INTRODUCTION
Thrombocytopenia is one of the two most common 
hematological problems in pregnant women. It is defined as 
a platelet count (PLT) below 150 × 103/μL, which can lead to 
acquired purpura. According to various sources, it concerns 
about 6.6–11.6% of women in the third trimester [1–3]. 
It should be noted that even in physiological pregnancy, 
a decrease of 10% in the platelet count could be observed 
[3–5]. Depending on the number of platelets, the following 
types of thrombocytopenia are distinguished:
 Ū mild thrombocytopenia: PLT 100–150 × 103/uL, 
 Ū moderate thrombocytopenia PLT 50–100 × 103/uL)
 Ū severe thrombocytopenia (PLT < 50 × 103/uL) [4].
The mechanism of the thrombocytopenia development 
is based on the impaired production or excessive destruc-
tion of platelets. Some causes of this phenomenon involve 
the immunological processes observed in diseases such as 
collagenoses, immune thrombocytopenic purpura (ITP), 
antiphospholipid syndrome, thrombotic microangiopathies, 
thrombotic thrombocytopenic purpura, haemolytic-uremic 
syndrome (HUS). Thrombocytopenia may also result from 
the use of drugs, viral infections, bone marrow dysfunc-
tion (bone marrow aplasia), nutritional deficiencies, or dis-
seminated intravascular coagulation syndrome (DIC) [6, 7]. 
Pregnant women are additionally exposed to thrombocyto-
penia due to obstetric reasons. These include preeclampsia, 
eclampsia, and particularly HELLP syndrome [4, 8]. Although 
thrombocytopenia in pregnant women usually has a mild 
course, in some cases a significant decrease in PLT count may 
lead to severe bleeding. In immune thrombocytopenia, low 
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levels of platelets in the fetus increase the risk of intracranial 
bleeding in the perinatal period. Besides, thrombocytopenia 
may be associated with pregnancy complications or a devel-
oping disease regardless of pregnancy. Since it is important 
to determine the cause of thrombocytopenia and to identify 
the risk for both the mother and the child [1].
GESTATIONAL INCIDENTAL 
THROMBOCYTOPENIA 
The most common form of this disease in pregnant 
women is GIT — gestational incidental thrombocytope-
nia. The incidence is estimated at 5%, which accounts for 
75% of all diagnosed cases of thrombocytopenia during 
pregnancy [3, 9]. Thrombocytopenia is a diagnosis of ex-
clusion. Usually, it is mild or moderate thrombocytopenia 
with a platelet count above 70 × 103/μL without the symp-
toms of purpura which does not occur before conceiving. 
The platelet count before and at the beginning of gestation 
usually falls within the normal range and after 1–12 weeks 
of its completion returns to normal values [10]. Its etiol-
ogy is unknown. It is believed that GIT is secondary to 
accelerated platelet destruction and increased plasma 
volume associated with pregnancy and seems to be a type 
of physiological thrombocytopenia. It develops usually 
in the second and third trimester of pregnancy. A mild or 
moderate decrease in the platelet count due to GIT is not 
associated with an increase in the ratio of maternal, fetal 
or neonatal complications, indicating that these condi-
tions do not require additional treatment except careful 
monitoring of platelet count [11, 12].
IMMUNE THROMBOCYTOPENIC PURPURA
Immune thrombocytopenic purpura (ITP), which may be 
the threat to the fetus, affects over 4% of pregnant women 
[13, 14]. It is moderate-degree thrombocytopenia with 
a platelet count below 100 × 103/uL before conceiving or 
at the beginning of gestation and a normal or increased 
megakaryocyte count in the bone marrow biopsy specimens 
[15]. During the diagnostic procedures, other systemic dis-
eases, splenomegaly or the use of drugs that may reduce 
the platelet count should be excluded. Pregnancy does not 
worsen the course of ITP, but there may be adverse fetal and 
maternal consequences in some cases. Although rare, spon-
taneous bleeding is the main maternal risk mainly when 
the platelet count falls below 20 × 103/uL [16]. Antiplatelet 
antibodies (predominantly IgG antibodies, less frequently 
IgM) lead to accelerated platelet destruction. Maternal IgG 
antibodies can pass through the placenta and bind to fetal 
platelets which results in the fetal thrombocytopenia de-
velopment. This is manifested by the appearance of bruises, 
petechiae, bleeding from the gastrointestinal tract, as well 
as intracranial hemorrhage in the neonatal period. Con-
genital thrombocytopenia during maternal ITP occurs in 
about 50% of newborns, and in 12–15% of newborns, the 
platelet count is below 50 × 103/uL [16, 17]. Serious hemor-
rhagic complications are reported in 3% of newborns, and 
in less than 1% of cases, intracranial bleeding occurs. Even 
if the maternal platelet count is within the normal range, 
the risk of having a baby with thrombocytopenia is ap-
proximately 30% [2]. Moderate to severe thrombocytopenia 
can cause a higher risk for both mothers and newborns, and 
the method of diagnosis, treatment or delivery is still the 
subject of debate [2, 7].
THROMBOCYTOPENIA DIAGNOSIS  
For establishing the cause of thrombocytopenia, it is 
very important to take a medical history, make physical 
examination and select appropriate laboratory tests. Based 
on the medical history, the following questions should be 
determined:
1. did thrombocytopenia occur before conception?
2. when did thrombocytopenia in the present pregnancy 
appear? 
3. did thrombocytopenia occurred in a child born before?
4. does the offspring develop properly without any neuro-
logical problems (delays in psychomotor development, 
cerebral palsy, epilepsy)
5.  is there a positive obstetrical history (miscarriage, still-
birth resulting from hemorrhage to the central nervous 
system)?
6. is thrombocytopenia an isolated disease or comorbid 
symptom? [18, 19]
Thrombocytopenia may be a symptom of serious dis-
eases complicating pregnancy itself, such as pregnancy 
induced hypertension, DIC, thrombotic microangiopathies 
(thromboembolic syndrome), thrombotic thrombocyto-
penic purpura [1]. The above-mentioned symptoms are 
presented in the following classification of the causes of 
thrombocytopenia during pregnancy.
Classification of thrombocytopenia in pregnancy:
1. Pregnancy-related thrombocytopenia:
•	 Gestational thrombocytopenia
•	 Thrombocytopenia during pregnancy-induced hy-
pertension (Gestora)
•	 HELLP syndrome (hemolysis, elevated liver function 
tests, low platelets count)
•	 Acute fatty liver of pregnancy




•	 Drug-induced thrombocytopenia (caused by hepa-
rin, gold preparations, quinidine, penicillin, cimeti-
dine, digoxin)
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•	 Thrombocytopenia in the course of viral infections 
(viruses that cross-react with platelet antigens, hu-
man immunodeficiency virus (HIV)
•	 Epstein-Barr-virus
•	 CMV (cytomegalovirus)
•	 Thrombotic microangiopathy syndrome
•	 Thrombotic thrombocytopenic purpura
•	 Hemolytic-uremic syndrome
•	 DIC (disseminated intravascular coagulation)




•	 Folic acid and vitamin B12 deficiency
•	 Hypersplenism
•	 Pseudothrombocytopenia
The basis for the diagnosis of thrombocytopenia in preg-
nant women is the use of automatic methods for the analysis 
of blood parameters, in combination with the reticulocytes 
count and evaluation of peripheral blood smear. Isolated 
thrombocytopenia is characteristic of both immune throm-
bocytopenia and gestational thrombocytopenia. There are 
large platelets in thrombocytopenia, which is indicated by 
increased platelet ratios — mean platelet volume (MPV) and 
platelet large cell ratio (P-LCR), which may exceed their norm. 
An extremely rare reason for the decreased isolated platelet 
count during pregnancy is sub-type IIB (2BvWD) and platelet 
type (PTvWD) of von Willebrand disease (vWD), which is 
the evidence of congenital thrombocytopenia. Thrombo-
cytopenia with increased reticulocytosis is observed dur-
ing microangiopathy. The assessment of peripheral blood 
smears is of great importance in the diagnosis. The presence 
of fragmentocytes and schistocytes in the smear becomes 
characteristic of thrombotic microangiopathy. Macrocytosis 
may be associated with myelodysplastic syndrome (MDS) 
or deficiency of vitamin B12 and folic acid. The presence 
of tear-shaped blood cells confirms bone marrow fibrosis. 
The precise evaluation of white blood cells makes it possible 
to diagnose neoplastic diseases of the blood that cause 
thrombocytopenia. In the case of isolated thrombocyto-
penia, the most likely diagnosis is GIT in the second half of 
pregnancy and ITP in the first half of pregnancy. In both cases, 
tests should be performed immediately to rule out second-
ary immune thrombocytopenia and other reasons for the 
isolated decrease in PLT count [1]. The following list presents 
the recommended laboratory tests in pregnant women.
Recommended laboratory tests in pregnant women 
with isolated thrombocytopenia:
1. Complete blood count with platelet and reticulocyte 
count
2. Peripheral blood smear
3. Hepatic enzymes and bilirubin
4. Direct antiglobulin test
5. Thyroid function tests
6. Antiphospholipid antibodies
7. Antinuclear antibodies
8. Test confirming infections: Helicobacter pylori, HCV, 
HBV, and HIV
9. Basic coagulation tests
10. Diagnostic tests for type 2BvWD and PTvWD von Wille-
brand disease.
THROMBOCYTOPENIA TREATMENT 
The goal of ITP treatment in pregnant women is to pre-
vent severe bleeding. Usually, in the second and third trimes-
ter, patients with PLT above 20 — 30 × 103/μL do not require 
treatment unless the invasive procedures are indicated. 
This treatment includes the administration of corticosteroids 
and intravenous immunoglobulin. Due to possible side ef-
fects of corticosteroids, it is recommended to start treatment 
with small doses, e.g., prednisone 10–20 mg/day for about 
7 days, adjusting the dose to PLT count [20]. According to the 
recommendations of the group of experts on hemostasis of 
the Polish Society of Hematology and Transplantologists the 
administration of prednisone in the initial dose of 1 mg/kg 
of body weight and its gradual reduction after PLT count 
increases above 5 × 103/μL. If the immediate increase in the 
PLT count is necessary, immunoglobulin should be offered at 
standard doses of 1g/kg of body weight for 1–2 days. After 
its transfusion, the PLT count increases in 24 — 48 hours 
and this effect lasts for 2–3 weeks. The immunoglobulin 
infusion can be repeated to ensure the optimal PLT count 
every 2–4 weeks until delivery. In the case of the resistance to 
first-line agents, a bone marrow biopsy should be performed 
to exclude other causes of thrombocytopenia. If the bone 
marrow is normal and the isolated thrombocytopenia has 
been revealed or worsened in late pregnancy, the test for 
the subtype 2BvWD and PTvWD of von Willebrand disease 
should be performed. The agents considered as safe by the 
Food and Drug Administration (FDA) in pregnancy with ITP is 
azathioprine at a dose of 1–2 mg/kg/body weight, which has 
a delayed effect [21]. Another drug approved for the treat-
ment of refractory ITP is cyclosporine. However, due to the 
frequent side effects, it is rarely used. The contra-indicated 
drugs during pregnancy are as follow cyclophosphamide, 
vinca alkaloids, mycophenolate mofetil and danazol [1, 22, 
23–25].
CONCLUSIONS
Thrombocytopenia in pregnancy is a mild condition, 
especially if it occurs in the last trimester. Its most common 
cause is GIT, and in the first trimester — ITP. Severe throm-
bocytopenia can be the reason for dangerous, hemorrhagic 
complications of pregnancy or the exacerbation of comor-
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bid disease. To diagnose the disease, it is essential to take 
an in-depth history and perform a physical examination. 
The key element in the diagnosis of thrombocytopenia is 
to use automated methods of analysis for evaluating the 
blood parameters. 
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